Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results, Misses Expectations By $0.18 EPS

Satellos Bioscience (NASDAQ:MSLE) released its earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18), Zacks reports.

Satellos Bioscience Stock Performance

NASDAQ MSLE traded down $0.20 on Thursday, hitting $9.82. The company’s stock had a trading volume of 46,664 shares, compared to its average volume of 49,999. Satellos Bioscience has a 52-week low of $4.84 and a 52-week high of $13.39. The firm’s 50-day simple moving average is $8.13. The firm has a market capitalization of $204.65 million, a price-to-earnings ratio of -6.14 and a beta of 1.51.

Wall Street Analyst Weigh In

A number of equities analysts have commented on MSLE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Wall Street Zen raised Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright increased their price objective on Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Wells Fargo & Company set a $18.00 target price on shares of Satellos Bioscience in a report on Thursday, July 9th. Finally, Guggenheim began coverage on shares of Satellos Bioscience in a research note on Tuesday, April 28th. They issued a “buy” rating and a $23.00 target price on the stock. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Satellos Bioscience has a consensus rating of “Moderate Buy” and an average price target of $19.75.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.